In this module, Jonathan Kay, MD, along with Beth Faiman, PhD, MSN, APN-BC, AOCN, course chair and Francis A. Farraye, MD, MSc, will review current clinical trial data, including registry data, of biosimilar therapeutics in patients with rheumatological disorders. The expert faculty will analyze recent studies, debating the clinical implications of each. Terms such as biosimilarity, changing and switching will also be clarified as they relate to treating patients with biosimilar agents. At the conclusion of this 30-minute interview segment, learners will gain insight into best practices for utilizing biosimilar agents in clinic to improve outcomes in patients with rheumatological disorders.
Healthcare professionals that treat inflammatory conditions, including gastroenterologists, rheumatologists, primary care practitioners, nurse practitioners, pharmacists and physician assistants
- Evaluate the science and clinical trial data of current and emerging biosimilars for the treatment of inflammatory conditions to improve the healthcare team’s understanding on the pharmacokinetic similarity, safety, and efficacy
Jonathan Kay, MD
Professor of Medicine and of Population and Quantitative Health Sciences
Timothy S. and Elaine L. Peterson Chair in Rheumatology
University of Massachusetts Medical School
University of Massachusetts Memorial Medical Center
Disclosures of Conflict of Interest
It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
|Faculty||Relationship Identified With:|
|Beth Faiman PhD, RN, MSN, CNP, AOCN, FAAN||Consultant/Advisor: Bristol-Myers Squibb Company; GlaxoSmithKline plc; Karyopharm Therapeutics; Sanofi|
|Jonathan Kay, MD||Consultant/Advisor: AbbVie, Inc.; Alvotech AG; Boehringer Ingelheim GmbH; Celltrion Healthcare Co.,Ltd; Mylan Pharma GmbH; Novartis Pharmaceuticals Corporation; Samsung Bioepis; Sandoz International GmbH; UCB, Inc.
Grant/Research Support: Pfizer Inc.
|Francis A. Farraye, MD, MSc||Consultant/Advisor: Braintree Laboratories; Bristol-Myers Squibb Company; Eli Lilly and Company; Gilead Sciences, Inc.; GI Reviewers, LLC; GlaxoSmithKline plc; Iterative Scopes, Inc; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; Sebela Pharmaceuticals Inc.; Theravance Biopharma
Stockholder: Innovation Pharmaceuticals
Planners and Peer Reviewers
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Nicole McMenamin, Emma Boring and Chelsey Benedek hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. This activity was planned by and for the healthcare team.
Credit Designation Statements
AcademicCME designates this live material for a maximum of 0.50 AMA PRA Category 1 Credits TM.
AcademicCME designates this enduring material for a maximum of 0.50 CNE Contact Hours, including 0.50 Pharmacotherapeutic Contact Hours (Provider Number P0491).
AcademicCME designates this continuing education activity for 0.50 CPE Contact Hours (0.05 CEUs) of continuing pharmacy education credit (UAN #: JA4008190-0000-20-018-H04-P).
Participants should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been supported by an independent educational grant from Pfizer Inc.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Pfizer Inc. do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
In order to claim credit, participants must complete the following:
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Learners who receive a grade of 66% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
- CPE credit will be posted to the learner’s CPE Monitor profile within 60 days of completion.
- CME and CNE credit will be issued appropriate certificate of completion.
- Others may request a “certificate of completion”.
- Learners should claim only the credit commensurate with the extent of their participation in the activity.
CE Inquiries/Special Needs
For all CE inquiries or special needs, please contact [email protected].